2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Diet, exercise and Parkinson’s
A recently published large new study provides strong evidence that consuming a healthy diet and engaging in physical activity may improve outcomes for people with Parkinson’s.
World Health Organisation (WHO) launches global strategy for Parkinson’s
The WHO have published a technical brief entitled Parkinson disease: a public health approach, outlining the global burden, treatment gaps and crucial areas for intervention in Parkinson’s.
A sub-study of azathioprine in Parkinson’s
There is increasing evidence that inflammation and the immune system might have contributory roles in the development and progression of Parkinson’s.
The influence of diabetes on Parkinson’s progression
In recent research funded by Cure Parkinson’s, scientists have provided the strongest evidence to date that diabetes can affect the progression of Parkinson’s.
Inhibikase makes a case for c-Abl
Research has suggested that in some cases of Parkinson’s a protein called c-Abl tyrosine kinase is abnormally over-active and this contributes to nerve cell inflammation and eventual cell death. The biotech company, Inhibikase, has been developing a drug which dampens down abnormal c-Abl protein.